Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $8.7 million.

  • Centessa Pharmaceuticals' Accounts Payables rose 1665.99% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 1665.99%. This contributed to the annual value of $7.1 million for FY2024, which is 3954.3% down from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Accounts Payables stood at $8.7 million, which was up 1665.99% from $5.7 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Accounts Payables high stood at $14.4 million for Q1 2023, and its period low was $5.1 million during Q1 2025.
  • For the 4-year period, Centessa Pharmaceuticals' Accounts Payables averaged around $9.0 million, with its median value being $8.2 million (2022).
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 11480.04% in 2023, then crashed by 5200.72% in 2024.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Accounts Payables stood at $13.8 million in 2022, then fell by 14.61% to $11.8 million in 2023, then plummeted by 39.54% to $7.1 million in 2024, then rose by 21.56% to $8.7 million in 2025.
  • Its Accounts Payables stands at $8.7 million for Q3 2025, versus $5.7 million for Q2 2025 and $5.1 million for Q1 2025.